

AMENDMENTS TO THE CLAIMS

Claim 1. (currently amended) A method for ~~the prophylaxis of non-inflammatory irritable bowel syndrome or for the treatment of one or more of~~ (a) non-inflammatory bowel disease, (b) diverticulosis, (c) diverticulitis, (and its complication diverticulitis), (d)-(e) diarrhoea-predominant irritable bowel syndrome, (e)-(d) irritable bowel syndrome, (f)-(e) one or more of bloating, diarrhoea, cramping, pain, low abdominal pain, distension, wind, flatulence, gas production, fluid secretion, mucus production, constipation, urgency or incontinence, when associated with a non-inflammatory bowel disease, diarrhoea-predominant irritable bowel syndrome or other non-specific non-inflammatory bowel disorder, (g)-(f) non ulcer dyspepsia, (h)-(g) spastic colon, (i)-(h) unstable colonic neurosis, (j)-(i) spastic colitis, (k)-(j) mucous colitis, (l)-(k) alternating constipation/diarrhoea, (m)-(l) alternating diarrhoea and constipation type IBS or (n)-(m) constipation IBS, comprising administering to a patient in need of such treatment ~~or prophylaxis~~ an effective amount of balsalazide or a salt thereof or a composition comprising balsalazide or a salt thereof together with a suitable carrier.

Claim 2. (original) A method according to claim 1 wherein the method alleviates symptoms of alternating diarrhoea and constipation type Irritable Bowel Syndrome or constipation predominant Irritable Bowel Syndrome.

Claim 3. (cancelled)

Claim 4. (original) A method according to claim 1 wherein the patient is a mammal.

Claim 5. (original) A method according to claim 4 wherein the patient is a human.

Claim 6. (previously presented) A method according to claim 1 wherein balsalazide is administered together with one or more of a 4-aminosalicylic acid or 5-aminosalicylic acid compound.

Claim 7. (previously presented) A method according to claim 6 wherein the 5-aminosalicylic acid or 4-aminosalicylic acid compound is mesalazine, olsalazine, sulfasalazine, ipsalazide, benzalazine, para-amino salicylic acid and pharmaceutically acceptable salts thereof.

Claim 8. (currently amended) A method according to claim 1 wherein balsalazide is administered together with olsalazine for the treatment or ~~prophylaxis~~ of diarrhoea predominant, constipation predominant or alternating diarrhoea and constipation type Irritable Bowel Syndrome.

Claim 9. (currently amended) A method according to claim 1 wherein balsalazide is administered together with mesalazine for the treatment or ~~prophylaxis~~ of diarrhoea predominant Irritable Bowel Syndrome.

Claim 10. (original) A method according to claim 1 wherein the balsalazide is administered together with anti-cholinergics, probiotics, antibiotics or anti-spasm medications.

Claim 11. (currently amended) A method for ~~the prophylaxis of non-inflammatory irritable bowel syndrome or~~ for the treatment of one or more of (a) non-inflammatory bowel disease, (b) diverticulosis, (c) diverticulitis, ~~(and its complication—diverticulitis), (d)(e)~~ diarrhoea-predominant irritable bowel

syndrome, (e)~~(d)~~ irritable bowel syndrome, (f)~~(e)~~ one or more of bloating, diarrhoea, cramping, pain, low abdominal pain, distension, wind, flatulence, gas production, fluid secretion, mucus production, constipation, urgency or incontinence, when associated with a non-inflammatory bowel disease, diarrhoea-predominant irritable bowel syndrome or other non-specific non-inflammatory bowel disorder, (g)~~(f)~~ non ulcer dyspepsia, (h)~~(g)~~ spastic colon, (i)~~(h)~~ unstable colonic neurosis, (j)~~(i)~~ spastic colitis, (k)~~(j)~~ mucous colitis, (l)~~(k)~~ alternating constipation/diarrhoea, (m)~~(l)~~ alternating diarrhoea and constipation type IBS or (n)~~(m)~~ constipation IBS, comprising administering to a patient in need of such treatment ~~or prophylaxis~~ an effective amount of a 4-aminosalicylic acid or 5-aminosalicylic acid compound, the 4-aminosalicylic acid or 5-aminosalicylic acid compound each modified to include a 4-aminobenzoyl- β -alanine side chain, or a salt thereof or a composition comprising the compound or a salt thereof together with a suitable carrier.

Claims 12-13. (cancelled)